rush_logo600x316v1.png
 

This conference is supported in part with an education grant 1R13CA268650-01 from the National Caner Institute of the NIH.

NIH logo.jpg

Endorsed By:

The Illinois American College of Cardiology (ACC) & The Chicago American Heart Association (AHA)

 

Conference Format

In-Person and Virtual Registration Options:
In-person conference being held at the conference facilities at Convene: 16 West Adams Street. Chicago, Illinois
The virtual conference will be available online via livestream

Venue Vaccine Policy
Convene’s goal is to create premium, safe spaces where people can work and meet comfortably and with peace of mind. In line with Convene’s commitment to protect the health and wellbeing of employees, customers, and guests, and in light of the rapidly spreading Delta variant of COVID-19, Convene is requiring that everyone onsite at our locations show proof of vaccination to prevent further spread of the virus in our communities. 

 Approved Forms of Proof of Vaccine
As part of the event check-in process, Convene will check for vaccine status at entry. Guests should plan to bring a photo ID and at least one of the following forms of proof:

  • State/city digital vaccine pass (ex: New York Excelsior pass)

  • A photo of your Center for Disease Control vaccine card

  • Or the hard copy of your Center for Disease Control vaccine card

  • International attendees can bring a photo or hard copy of an official vaccination record of a COVID-19 vaccine administered outside the United States, including AstraZeneca/SK Bioscience, Serum Institute of India/COVISHIELD, Vaxzevria, Sinopharm, or Sinovac


Can I take a PCR or rapid test instead to attend this event?
At this time, Convene is requiring that everyone onsite show proof of vaccination status and are not accepting tests as a substitute for proof of vaccination.

Program Information

Cardiovascular disease and cancer are the #1 and #2 causes of death in the United States. Both conditions involve many variables and their study is constant and diffuse. Cardio-oncology is a nascent field which focuses on preventing adverse cardiovascular outcomes in patients with active cancer; and improving the overall cardiovascular health of cancer survivors. This involves specific understanding of interactions between cancer and the cardiovascular system; as well as intrinsic knowledge of cancer therapeutic agents including chemotherapy, radiation therapy, and newer targeted therapies which include immunotherapy, such as immune checkpoint inhibitors and Car-T cell therapy. Furthermore, recent developments in the medical management of cardiac disease (such as SGLT-2 inhibitors and ivabradine) present new therapeutic options for affected cancer patients and survivors. With such rapid change, clinicians often find it difficult to remain up-to-date with the best means of identifying and treating patients. The purpose of this program is to familiarize primary care providers, hospitalists, oncologists, cardiologists, advanced practice providers, pharmacists and trainees with updated treatment of cardiac conditions seen in cancer patients and survivors.

Educational Goal
To provide state-of-the art best practice information regarding the continuum of cardiac care for the oncology patient.

Target Audience
This activity has been planned for Primary Care Providers, Hospitalists, Oncologists, Cardiologists, Advanced Practice Providers, Pharmacists, Nurses and Medical Trainees interested in learning about the field of Cardio-Oncology.

Accreditation / Designation
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Rush University Medical Center designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this live activity for a maximum of 7.75 nursing contact hour(s).

Rush University Medical Center designates this knowledge-based live activity for a maximum of 7.75 contact hour(s) for pharmacists.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

1. Define the risks of cancer treatment-related cardiac dysfunction for patients who have undergone therapy for cancer.

2. Provide some knowledge of cardiovascular effects of newer cancer therapies; as well as the potential use of newer cardiac drugs for management of cardiovascular complications associated with cancer
therapy.

3. Implement strategies for early detection, correction of cardiac risk factors and close, as well as long-term cardiovascular monitoring in order to reduce the effects of cardiotoxicity (including arrhythmias, heart failure, severe hypertension, valvular heart disease, pericardial disease, and
autonomic dysfunction) for patients who are at risk for cancer treatment-related cardiac dysfunction.

4. Assess appropriate and effective treatment strategies and referral for patients who have (or are at risk for) long-term toxicity-related cardiac
dysfunction, including heart failure, valvular dysfunction, hypertension, and autonomic dysfunction.

Unapproved Uses of Drugs/Devices

In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/ device for full prescribing/utilization information.